Table 2.
Characteristics of steatotic and non-steatotic patients, n (%)
|
|
Patients with steatosis (n = 85)
|
Patients without steatosis (n = 20)
|
P value
|
| Demographic and anthropometric data | |||
| Sex (male) | 40 (47) | 11 (55) | 0.62 |
| Age (yr) | 56 ± 14 | 53 ± 14 | 0.5 |
| BMI (kg/m2) | 31 ± 5 | 28 ± 6 | 0.0004 |
| Normal BMI | 7 (8) | 4 (20) | |
| Overweight | 31 (37) | 13 (65) | |
| Obesity | 47 (55) | 3 (15) | |
| Waist circumference (cm)1 | 108 ± 14 | 99 ± 15 | 0.004 |
| Diabetes | 33 (39) | 5 (25) | 0.3 |
| Hypertension | 37 (44) | 5 (25) | 0.2 |
| Metabolic syndrome | 65 (76) | 8 (40) | 0.0026 |
| Biological data | |||
| Platelets count (G/L)1 | 236 ± 71 | 213 ± 78 | 0.2 |
| AST (U/L)1 | 37 ± 30 | 27 ± 10 | 0.13 |
| ALT (U/L)1 | 37 ± 30 | 49 ± 29 | 0.044 |
| GGT (U/L)1 | 68 ± 53 | 116 ± 85 | 0.68 |
| Triglycerides (g/L)1 | 1.8 ± 0.9 | 1.3 ± 0.9 | 0.0058 |
| HDL cholesterol (g/L)1 | 1.3 ± 0.4 | 1.3 ± 0.3 | 0.1 |
| Ferritin (ng/mL)1 | 121 ± 134 | 172 ± 127 | 0.45 |
| Steatosis assessment | |||
| PDFF (%)1 | 18 ± 9 | 2 ± 3 | < 0.0001 |
| Fibroscan® | |||
| Technical success | 84 (99) | 20 (100) | |
| cCAP (dB/m) | 296 ± 42 | 246 ± 67 | < 0.0001 |
| Liver stiffness (KPa)1 | 8 ± 8 | 7 ± 5 | NS |
| Liver stiffness > 10 KPa | 19 (22) | 2 (10) | |
| Use of M probe | 65 (76) | 18 (90) | |
| Use of XL probe | 20 (24) | 2 (10) | |
| Aixplorer MACH 30® | |||
| Technical success | 85 (100) | 20 (100) | |
| SSE (m/s)1 | 1515 ± 22 | 1533 ± 19 | 0.0009 |
| AC (dB/cm/MHz)1 | 0.5 ± 0.1 | 0.39 ± 0.1 | < 0.0001 |
| HRI | 1.52 ± 0.24 | 1.1 ± 0.18 | < 0.0001 |
| Technical success | 84 (99) | 20 (100) | |
1
Data are mean ± SD.
BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma glutamyl transferase; PDFF: Proton density fat fraction; cCAP: Continuous controlled attenuation parameter; SSE: Sound speed estimation; AC: Attenuation coefficient; HRI: Hepato-renal index; NS: Non-significant.